Regulation of interleukin 1α secretion by inflammasomes

Annals of the Rheumatic Diseases

Volumn 72, Issue SUPPL. 2, 2013, Pages

  Yazdi, Amir S ^a   Drexler, Stefan K ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CANAKINUMAB; INFLAMMASOME; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT;

ARTICLE; ATHEROSCLEROSIS; CINCA SYNDROME; CYTOKINE RELEASE; DISEASE COURSE; DRUG EFFICACY; FAMILIAL MEDITERRANEAN FEVER; GOUT; HUMAN; INFLAMMATION; JUVENILE RHEUMATOID ARTHRITIS; MUCKLE WELLS SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; REGULATORY MECHANISM; RHEUMATOID ARTHRITIS; SCHNITZLER SYNDROME; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME;

ANIMALS; GENE EXPRESSION REGULATION; HUMANS; INFLAMMASOMES; INFLAMMATION; INTERLEUKIN-1ALPHA; MICE;

EID: 84876284629     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202252     Document Type: Article

References (40)

1. Hoffman HM, Rosengren S, Boyle DL, et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004;364:1779-85. (Pubitemid 39488063)
2. Aksentijevich I, Nowak M, Mallah M, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 2002;46:3340-8. (Pubitemid 35453546)
3. Hoffman HM, Mueller JL, Broide DH, et al. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001;29:301-5. (Pubitemid 33096455)
4. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009;360:2416-25.
5. Hawkins PN, Lachmann HJ, Aganna E, et al. Spectrum of clinical features in Muckle-Wells syndrome and response to Anakinra. Arthritis Rheum 2004;50:607-12. (Pubitemid 38198844)
6. Hoffman HM, Throne ML, Amar NJ, et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008;58:2443-52.
7. Meinzer U, Quartier P, Alexandra J-F, et al. Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum 2011;41:265-71.
8. Obici L, Meini A, Cattalini M, et al. Favourable and sustained response to Anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis. Ann Rheum Dis 2011;70:1511-12.
9. Schnellbacher C, Ciocca G, Menendez R, et al. Deficiency of interleukin-1 receptor antagonist responsive to Anakinra. Pediatr Dermatol. Published Online First: 4 April 2012. doi:10.1111/j.1525-1470.2012.01725.x
10. Launois R, Avouac B, Berenbaum F, et al. Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis. J Rheumatol 2011;38:835-45.
11. Alten R, Gomez-Reino J, Durez P, et al. Efficacy and safety of the human anti-IL-1β monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study. BMC Musculoskelet Disord 2011;12:153.
12. Laskari K, Tzioufas AG, Moutsopoulos HM. Efficacy and long-term follow-up of IL-1R inhibitor Anakinra in adults with still's disease: a case-series study. Arthritis Res Ther 2011;13:R91.
13. Kontzias A, Efthimiou P. The use of canakinumab, a novel IL-1β long-acting inhibitor, in refractory adult-onset still's disease. Semin Arthritis Rheum. Published Online First: 16 April 2012. doi:10.1016/j. semarthrit.2012.03.004
14. Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007;356:1517-26. (Pubitemid 46588416)
15. So A, De Smedt T, Revaz S, et al. A pilot study of IL-1 inhibition by Anakinra in acute gout. Arthritis Res Ther 2007;9:R28.
16. Schlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 2012;71:1839-48.
17. Schumacher HR Jr, Sundy JS, Terkeltaub R, et al. Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2012;64:876-84.
18. Krause K, Weller K, Stefaniak R, et al. Efficacy and safety of the interleukin-1 antagonist Rilonacept in Schnitzler syndrome: an open-label study. Allergy. 2012;67:943-50.
19. Brenner M, Ruzicka T, Plewig G, et al. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist Anakinra. Br J Dermatol 2009;161:1199-1201.
20. Nigrovic PA, Mannion M, Prince FHM, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 2011;63:545-55.
21. Morton AC, Foley C, Rothman A, et al. 15 Investigation of IL-1 inhibition in patients presenting with non-ST elevation myocardial infarction acute coronary syndromes (the MRC-ILA Heart Study). Heart 2011;97:A13.
22. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009;27:519-50.
23. Yazdi AS, Guarda G, D'Ombrain MC, et al. Inflammatory caspases in innate immunity and inflammation. J Innate Immun 2010;2:228-37.
24. Schroder K, Tschopp J. The inflammasomes. Cell 2010;140:821-32.
25. Yazdi AS, Drexler SK, Tschopp J. The role of the inflammasome in nonmyeloid cells. J Clin Immunol 2010;30:623-7.
26. Chen C-J, Kono H, Golenbock D, et al. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med 2007;13:851-6. (Pubitemid 47038190)
27. Eigenbrod T, Park J-H, Harder J, et al. Cutting edge: critical role for mesothelial cells in necrosis-induced inflammation through the recognition of IL-1 alpha released from dying cells. J Immunol 2008;181:8194-8.
28. Howard AD, Kostura MJ, Thornberry N, et al. IL-1-converting enzyme requires aspartic acid residues for processing of the IL-1 beta precursor at two distinct sites and does not cleave 31-kDa IL-1 alpha. J Immunol 1991;147:2964-9.
29. Guarda G, Braun M, Staehli F, et al. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 2011;34:213-23.
30. Keller M, Rüegg A, Werner S, et al. Active caspase-1 is a regulator of unconventional protein secretion. Cell 2008;132:818-31. (Pubitemid 351312798)
31. Yazdi AS, Guarda G, Riteau N, et al. Nanoparticles activate the NLR pyrin domain containing 3 (Nlrp3) inflammasome and cause pulmonary inflammation through release of IL-1 and IL-1. Proc Nat Acad Sci 2010;107:19449-54.
32. Fantuzzi G, Zheng H, Faggioni R, et al. Effect of endotoxin in IL-1 beta-deficient mice. J Immunol 1996;157:291-6. (Pubitemid 26190560)
33. Joosten LAB, Van De Veerdonk FL, Vonk AG, et al. Differential susceptibility to lethal endotoxaemia in mice deficient in IL-1α, IL-1β or IL-1 receptor type I. APMIS 2010;118:1000-7.
34. Lamkanfi M, Sarkar A, Vande Walle L, et al. Inflammasome-dependent release of the alarmin HMGB1 in endotoxemia. J Immunol 2010;185:4385-92.
35. Li H, Ambade A, Re F. Cutting edge: necrosis activates the NLRP3 inflammasome. J Immunol 2009;183:1528-32.
36. Vonk AG, Netea MG, van Krieken JH, et al. Endogenous interleukin (IL)-1 alpha and IL-1 beta are crucial for host defense against disseminated candidiasis. J Infect Dis 2006;193:1419-26. (Pubitemid 43673390)
37. Zheng H, Fletcher D, Kozak W, et al. Resistance to fever induction and impaired acute-phase response in interleukin-1 beta-deficient mice. Immunity 1995;3:9-19.
38. Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010;464:1357-61.
39. Gross O, Yazdi AS, Thomas CJ, et al. Inflammasome activators induce interleukin-1α secretion via distinct pathways with differential requirement for the protease function of caspase-1. Immunity 2012;36:388-400.
40. Fettelschoss A, Kistowska M, Leibund Gut-Landmann S, et al. Inflammasome activation and IL-1β target IL-1α for secretion as opposed to surface expression. Proc Natl Acad Sci USA 2011;108:18055-60.